Lingus schreef op 1 juli 2019 22:13:
Celyad Announces Strategic Updates to the Autologous r/r AML and MDS Program
Mon July 1, 2019 4:01 PM|GlobeNewswire|About: CYAD
Regulators accept proposal to utilize OptimAb manufacturing process, which enriches for T cells with memory-like phenotype, with CYAD-01 under current IND application
FDA accepts IND application, including OptimAb manufacturing process, for CYAD-02—next-generation NKG2D-based CAR-T therapy focused on improved persistence. CYAD-02 Phase 1 trial scheduled to start in early 2020
Today’s updates to our r/r AML and MDS program are built on the clinical profile seen to date for CYAD-01 and focus on increasing the potency of NKG2D-based CAR-Ts in order to drive towards Phase 2 clinical development
Management to hold a conference call on Tuesday, July 2nd, at 2 p.m. CEDT/ 8 a.m. EDT
Zie verder: seekingalpha.com/pr/17560878-celyad-a...